

Flavone

Mark P. Waller,^{a*} David E. Hibbs,^a Jacob Overgaard,^a Jane R. Hanrahan^b and Trevor W. Hambley^a

^aSchool of Chemistry, University of Sydney, NSW 2006, Australia, and ^bFaculty of Pharmacology, University of Sydney, NSW 2006, Australia

Correspondence e-mail: m.waller@chem.usyd.edu.au

Key indicators


Single-crystal X-ray study
 $T = 150$ K
 Mean $\sigma(\text{C}-\text{C}) = 0.003$ Å
 R factor = 0.038
 wR factor = 0.108
 Data-to-parameter ratio = 9.8

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

In the title molecule, $\text{C}_{15}\text{H}_{10}\text{O}_2$, there are two molecules in the asymmetric unit. The γ -pyrone ring makes a dihedral angle of 1.0 (1)° with the 2-phenyl substituent in one of the molecules, while in the other molecule the γ -pyrone ring makes a dihedral angle of 9.8 (1)° with the 2-phenyl substituent.

Comment

Flavones and related compounds are known to exhibit a wide range of interesting biological activities (Agullo *et al.*, 1997; Carlo *et al.*, 1993; Miksicek, 1993; Wang *et al.*, 1999). Flavone is the parent molecule of a number of flavones that have interesting modulatory activities at GABA-A receptors (Medina *et al.*, 1998; Chebib & Johnston, 2000). The title compound, (I), was crystallized as part of an ongoing structure–activity study to determine the properties of those compounds that confer this activity in order to aid the design of more active compounds.



All bond lengths and angles in (I) are as expected.

Experimental

The sample of flavone was obtained from Sigma–Aldrich. Single crystals of (I) were grown by slow evaporation of a methanol solution. Crystals of (I) were mounted using silicone oil which acted as both a coating and an adhesive.

Crystal data

$\text{C}_{15}\text{H}_{10}\text{O}_2$
 $M_r = 222.23$
 Orthorhombic, $P2_12_12_1$
 $a = 8.281$ (2) Å
 $b = 13.216$ (4) Å
 $c = 19.737$ (6) Å
 $V = 2159.9$ (11) Å³
 $Z = 8$
 $D_x = 1.367$ Mg m⁻³

Mo $K\alpha$ radiation
 Cell parameters from 999 reflections
 $\theta = 1.9$ – 28.3°
 $\mu = 0.09$ mm⁻¹
 $T = 150$ (2) K
 Block, colourless
 $0.40 \times 0.25 \times 0.25$ mm

Data collection

Bruker SMART CCD diffractometer
 ω scans
 14 562 measured reflections
 3010 independent reflections
 2762 reflections with $I > 2\sigma(I)$

$R_{\text{int}} = 0.023$
 $\theta_{\text{max}} = 28.3^\circ$
 $h = -11 \rightarrow 10$
 $k = -16 \rightarrow 17$
 $l = -26 \rightarrow 25$




Figure 1
A general view of the asymmetric unit of (I). Ellipsoids are drawn at the 50% probability level.

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.038$
 $wR(F^2) = 0.108$
 $S = 1.08$
 3010 reflections
 307 parameters
 H-atom parameters constrained

$$w = 1/[\sigma^2(F_o^2) + (0.0679P)^2 + 0.3747P]$$

where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\max} = 0.001$
 $\Delta\rho_{\max} = 0.36 \text{ e } \text{\AA}^{-3}$
 $\Delta\rho_{\min} = -0.18 \text{ e } \text{\AA}^{-3}$

The H atoms were constrained at idealized positions.

Data collection: *SMART* (Bruker, 1995); cell refinement: *SMART* (Bruker, 1995); data reduction: *SAINT-Plus* (Bruker, 1995); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1990); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP-3 for Windows* (Farrugia, 1997); software used to prepare material for publication: *SHELXL97*.

The authors thank the Australian Research Council for funding.

References

- Agullo, G., Gamet-Payrastre, L., Manenti, S., Viala, C., Remesy, C., Chap, H. & Payrastre, B. (1997). *Biochem. Pharmacol.* **53**, 1649–1657.
- Bruker (1995). *SMART* and *SAINT-Plus*. Bruker AXS Inc., Madison, Wisconsin, USA.
- Carlo, G. D., Autore, G., Izzo, A. A., Maiolino, P., Mascolo, N., Viola, P., Diurno, M. V. & Capasso, F. (1993). *J. Pharm. Pharmacol.* **45**, 1054–1059.
- Chebib, M. & Johnston, G. A. R. (2000). *J. Med. Chem.* **43**, 1427–1447.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Medina, J. H., Viola, H., Wolfman, C., Marder, M., Wasowski, C., Calvo, D. & Paladini, A. C. (1998). *Phytomedicine*, **5**, 235–243.
- Miksicek, R. J. (1993). *Mol. Pharmacol.* **44**, 37–43.
- Sheldrick, G. M. (1990). *Acta Cryst.* **A46**, 467–473.
- Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
- Wang, I.-K., Lin-Shiau, S.-Y. & Lin, J.-K. (1999). *Eur. J. Cancer*, **35**, 1517–1525.